Data from the ATLAS research comprises a series of trials that have yielded years of long-term, comprehensive data on safety ...

The current state of treatment for geographic atrophy is marked by two approved therapies that slow GA progression: ...

Mural Oncology's stock plummeted 57% after halting the Phase 3 ARTISTRY-7 trial for nemvaleukin alfa. Click here to read an ...

BioNTech has shown why it made small cell lung cancer (SCLC) a priority for its PD-L1xVEGF-A bispecific. | BioNTech has shown ...

Final overall survival results show amivantamab plus lazertinib beat out osimertinib for first-line treatment of advanced ...